Page 363 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C2.1. Eligibility criteria, follow-up protocols, triggers for intervention and definition of progression in cohorts of active
surveillance/ watchful waiting/other observational management strategies (continued)

Center, Country Eligibility criteria Followup or monitoring protocol Triggers for intervention/ Definition of
[PMID] active therapy progression
Enrollment year
Memorial Sloan- Low-risk prostate Semiannually with DRE, free and total PSA measurements, and Treatment was recommended NR
Kettering Cancer cancer patients a review of general health and urinary symptoms. Biopsy was when the patient no longer
Center, US 115 who were routinely recommended within 12 to 18 months of starting AS met study eligibility criteria
[21167529] eligible for AS; and subsequently repeated every 2 to 3 yr or as needed. during followup.
PSA <10
1997-2009 ng/mL, no
prostate biopsy
Gleason grade
4 or 5, clinical
state T1-T2a,
≤3 positive
biopsy cores
(minimum 10),
no biopsy core
containing
>50% cancer
involvement
and
confirmatory
biopsy to
reassess
eligibility before
starting AS

C-99